These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 22338015)

  • 1. Copy number gain of 1q25 predicts poor progression-free survival for pediatric intracranial ependymomas and enables patient risk stratification: a prospective European clinical trial cohort analysis on behalf of the Children's Cancer Leukaemia Group (CCLG), Societe Francaise d'Oncologie Pediatrique (SFOP), and International Society for Pediatric Oncology (SIOP).
    Kilday JP; Mitra B; Domerg C; Ward J; Andreiuolo F; Osteso-Ibanez T; Mauguen A; Varlet P; Le Deley MC; Lowe J; Ellison DW; Gilbertson RJ; Coyle B; Grill J; Grundy RG
    Clin Cancer Res; 2012 Apr; 18(7):2001-11. PubMed ID: 22338015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma.
    Mendrzyk F; Korshunov A; Benner A; Toedt G; Pfister S; Radlwimmer B; Lichter P
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2070-9. PubMed ID: 16609018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrating Tenascin-C protein expression and 1q25 copy number status in pediatric intracranial ependymoma prognostication: A new model for risk stratification.
    Andreiuolo F; Le Teuff G; Bayar MA; Kilday JP; Pietsch T; von Bueren AO; Witt H; Korshunov A; Modena P; Pfister SM; Pagès M; Castel D; Giangaspero F; Chimelli L; Varlet P; Rutkowski S; Frappaz D; Massimino M; Grundy R; Grill J;
    PLoS One; 2017; 12(6):e0178351. PubMed ID: 28617804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of chromosome 1q gain in intracranial ependymomas.
    Rajeshwari M; Sharma MC; Kakkar A; Nambirajan A; Suri V; Sarkar C; Singh M; Saran RK; Gupta RK
    J Neurooncol; 2016 Apr; 127(2):271-8. PubMed ID: 26725097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-time quantitative PCR analysis of pediatric ependymomas identifies novel candidate genes including TPR at 1q25 and CHIBBY at 22q12-q13.
    Karakoula K; Suarez-Merino B; Ward S; Phipps KP; Harkness W; Hayward R; Thompson D; Jacques TS; Harding B; Beck J; Thomas DG; Warr TJ
    Genes Chromosomes Cancer; 2008 Nov; 47(11):1005-22. PubMed ID: 18663750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular staging of intracranial ependymoma in children and adults.
    Korshunov A; Witt H; Hielscher T; Benner A; Remke M; Ryzhova M; Milde T; Bender S; Wittmann A; Schöttler A; Kulozik AE; Witt O; von Deimling A; Lichter P; Pfister S
    J Clin Oncol; 2010 Jul; 28(19):3182-90. PubMed ID: 20516456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chromosome 1q gain and tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymoma.
    Araki A; Chocholous M; Gojo J; Dorfer C; Czech T; Heinzl H; Dieckmann K; Ambros IM; Ambros PF; Slavc I; Haberler C
    Acta Neuropathol Commun; 2016 Aug; 4(1):88. PubMed ID: 27550150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telomerase activation in posterior fossa group A ependymomas is associated with dismal prognosis and chromosome 1q gain.
    Gojo J; Lötsch D; Spiegl-Kreinecker S; Pajtler KW; Neumayer K; Korbel P; Araki A; Brandstetter A; Mohr T; Hovestadt V; Chavez L; Kirchhofer D; Ricken G; Stefanits H; Korshunov A; Pfister SM; Dieckmann K; Azizi AA; Czech T; Filipits M; Kool M; Peyrl A; Slavc I; Berger W; Haberler C
    Neuro Oncol; 2017 Sep; 19(9):1183-1194. PubMed ID: 28371821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct disease-risk groups in pediatric supratentorial and posterior fossa ependymomas.
    Godfraind C; Kaczmarska JM; Kocak M; Dalton J; Wright KD; Sanford RA; Boop FA; Gajjar A; Merchant TE; Ellison DW
    Acta Neuropathol; 2012 Aug; 124(2):247-57. PubMed ID: 22526017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.
    Goschzik T; Schwalbe EC; Hicks D; Smith A; Zur Muehlen A; Figarella-Branger D; Doz F; Rutkowski S; Lannering B; Pietsch T; Clifford SC
    Lancet Oncol; 2018 Dec; 19(12):1602-1616. PubMed ID: 30392813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gain of 1q As a Prognostic Biomarker in Wilms Tumors (WTs) Treated With Preoperative Chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study.
    Chagtai T; Zill C; Dainese L; Wegert J; Savola S; Popov S; Mifsud W; Vujanić G; Sebire N; Le Bouc Y; Ambros PF; Kager L; O'Sullivan MJ; Blaise A; Bergeron C; Mengelbier LH; Gisselsson D; Kool M; Tytgat GA; van den Heuvel-Eibrink MM; Graf N; van Tinteren H; Coulomb A; Gessler M; Williams RD; Pritchard-Jones K
    J Clin Oncol; 2016 Sep; 34(26):3195-203. PubMed ID: 27432915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conformal Radiation Therapy for Pediatric Ependymoma, Chemotherapy for Incompletely Resected Ependymoma, and Observation for Completely Resected, Supratentorial Ependymoma.
    Merchant TE; Bendel AE; Sabin ND; Burger PC; Shaw DW; Chang E; Wu S; Zhou T; Eisenstat DD; Foreman NK; Fuller CE; Anderson ET; Hukin J; Lau CC; Pollack IF; Laningham FH; Lustig RH; Armstrong FD; Handler MH; Williams-Hughes C; Kessel S; Kocak M; Ellison DW; Ramaswamy V
    J Clin Oncol; 2019 Apr; 37(12):974-983. PubMed ID: 30811284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histopathological grading of pediatric ependymoma: reproducibility and clinical relevance in European trial cohorts.
    Ellison DW; Kocak M; Figarella-Branger D; Felice G; Catherine G; Pietsch T; Frappaz D; Massimino M; Grill J; Boyett JM; Grundy RG
    J Negat Results Biomed; 2011 May; 10():7. PubMed ID: 21627842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A retrospective analysis of recurrent pediatric ependymoma reveals extremely poor survival and ineffectiveness of current treatments across central nervous system locations and molecular subgroups.
    Ritzmann TA; Rogers HA; Paine SML; Storer LCD; Jacques TS; Chapman RJ; Ellison D; Donson AM; Foreman NK; Grundy RG
    Pediatr Blood Cancer; 2020 Sep; 67(9):e28426. PubMed ID: 32614133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing biomarkers for accurate ependymoma diagnosis, prognostication, and stratification within International Clinical Trials: A BIOMECA study.
    Chapman RJ; Ghasemi DR; Andreiuolo F; Zschernack V; Espariat AT; Buttarelli FR; Giangaspero F; Grill J; Haberler C; Paine SML; Scott I; Jacques TS; Sill M; Pfister S; Kilday JP; Leblond P; Massimino M; Witt H; Modena P; Varlet P; Pietsch T; Grundy RG; Pajtler KW; Ritzmann TA
    Neuro Oncol; 2023 Oct; 25(10):1871-1882. PubMed ID: 36916248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of novel chromosomal abnormalities and prognostic cytogenetics markers in intracranial pediatric ependymoma.
    Pezzolo A; Capra V; Raso A; Morandi F; Parodi F; Gambini C; Nozza P; Giangaspero F; Cama A; Pistoia V; Garrè ML
    Cancer Lett; 2008 Mar; 261(2):235-43. PubMed ID: 18179864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isochromosome 1q as an early genetic event in a child with intracranial ependymoma characterized by molecular cytogenetics.
    Granzow M; Popp S; Weber S; Schoell B; Holtgreve-Grez H; Senf L; Hager D; Boschert J; Scheurlen W; Jauch A
    Cancer Genet Cytogenet; 2001 Oct; 130(1):79-83. PubMed ID: 11672779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systematic review of treatment outcomes in pediatric patients with intracranial ependymomas.
    Cage TA; Clark AJ; Aranda D; Gupta N; Sun PP; Parsa AT; Auguste KI
    J Neurosurg Pediatr; 2013 Jun; 11(6):673-81. PubMed ID: 23540528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival and prognostic factors following radiation therapy and chemotherapy for ependymomas in children: a report of the Children's Cancer Group.
    Robertson PL; Zeltzer PM; Boyett JM; Rorke LB; Allen JC; Geyer JR; Stanley P; Li H; Albright AL; McGuire-Cullen P; Finlay JL; Stevens KR; Milstein JM; Packer RJ; Wisoff J
    J Neurosurg; 1998 Apr; 88(4):695-703. PubMed ID: 9525716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular grouping and outcomes of young children with newly diagnosed ependymoma treated on the multi-institutional SJYC07 trial.
    Upadhyaya SA; Robinson GW; Onar-Thomas A; Orr BA; Billups CA; Bowers DC; Bendel AE; Hassall T; Crawford JR; Partap S; Fisher PG; Tatevossian RG; Seah T; Qaddoumi IA; Vinitsky A; Armstrong GT; Sabin ND; Tinkle CL; Klimo P; Indelicato DJ; Boop FA; Merchant TE; Ellison DW; Gajjar A
    Neuro Oncol; 2019 Oct; 21(10):1319-1330. PubMed ID: 30976811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.